Wall Street expects a year-over-year increase in earnings on higher revenues when BioCryst Pharmaceuticals (BCRX) reports results for the...
2 days ago

Read abrdn plc Acquires New Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) at Defense World.
2 days ago

It was great to see such a strong Q4 and full year 2023 for ORLADEYO. Not just the revenue performance, but the continued underlying strength in...
2 months ago

Hoover council OKs $1.8 million in tax breaks for BioCryst Pharmaceuticals expansion ... The Hoover City Council on Monday night approved $1.8...
5 months ago

Key Insights Significantly high institutional ownership implies BioCryst Pharmaceuticals' stock price is sensitive to...
1 week ago

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. On 31...
1 month ago

A Durham-based pharmaceutical company laid off 10% of its workforce, but its stock price jumped by more than 25% Monday after it reported...
3 months ago

BioCryst Pharmaceuticals (BCRX) has disclosed a new risk, in the Regulation category. BioCryst Pharmaceuticals' capacity to manage...
2 months ago

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) shares hit a new 52-week low on Thursday . The company traded as low as $4.15...
4 days ago

Over three years, BioCryst Pharmaceuticals grew revenue at 56% per year. That's well above most other pre-profit companies. The share price has...
1 month ago